The kidney question is the strongest of the PPI safety concerns — stronger than the dementia one, and worth taking seriously. Several large observational studies have found that long-term PPI users develop chronic kidney disease at higher rates than non-users, with hazard ratios generally in the 1.2 to 1.5 range, and with twice-daily dosing carrying more risk than once-daily.
But the only large randomized trial to test it — 17,598 people taking pantoprazole or placebo for three years — found no significant difference in chronic kidney disease.
So the honest answer is: there’s a real mechanism, a consistent signal in observational data, and no confirmation from the one study design that could settle it. That’s not nothing, and it’s not proof. What I’d take from it is that dose and duration matter, and that staying on a PPI which isn’t helping your throat is a poor trade.
Key Takeaways
- PPIs can cause acute interstitial nephritis — an inflammatory kidney reaction. This one is genuinely established, though rare.
- Observational studies link long-term PPI use to chronic kidney disease, with hazard ratios around 1.2–1.5.
- Twice-daily dosing showed higher risk than once-daily (1.46 vs 1.15), which is the kind of dose-response pattern that argues for a real effect.
- One large study found the CKD association persisted even in people who never had a documented acute kidney injury.
- The COMPASS randomized trial, 17,598 people over three years, found no significant increase in chronic kidney disease.
- A systematic review judged the observational studies to carry moderate to serious risk of bias, mostly from inadequate confounder control.
- Practical upshot: use the lowest dose that works, for the shortest time that’s justified — and if it isn’t working, that’s a reason to change approach, not to continue.
The one kidney risk that isn’t in doubt
Before the chronic kidney disease debate, there’s a separate and better-established issue: acute interstitial nephritis.
This is an allergic-type inflammatory reaction in the kidney tissue, and PPIs are among the drugs known to trigger it. It’s idiosyncratic — not dose-related, not predictable, and it can appear weeks or months into treatment. It’s rare, but it’s real, and unlike the CKD question it isn’t a statistical argument.
The reason it matters is that acute interstitial nephritis is often silent. There’s frequently no pain and no obvious warning; it shows up as a rise in creatinine on a routine blood test. Left undetected, it can leave permanent scarring.
This is the honest case for having kidney function checked if you’ve been on a PPI long-term — not because the drug is likely to harm you, but because the one clearly-established kidney effect is the sort that doesn’t announce itself.
What the chronic kidney disease research found
In 2016, researchers analyzed the Atherosclerosis Risk in Communities study — 10,482 people with normal kidney function at baseline, followed for over a decade — and found PPI use associated with incident chronic kidney disease at a hazard ratio of 1.50 after adjustment. They then replicated it in a separate cohort of 248,751 patients, where the figure was 1.24.
Two details from that paper stand out. First, when they compared PPI users directly against H2 blocker users — people taking a different acid-suppressing drug for similar reasons, which controls for some of the “sicker people take more drugs” problem — the association held at 1.39. Second, twice-daily dosing carried a higher risk (1.46) than once-daily (1.15) [Lazarus et al., JAMA Internal Medicine, 2016].
That dose-response gradient is the part that gives the finding weight. Confounding can produce an association; it’s less good at producing a neat dose-response curve.
A follow-up question was whether the chronic damage was simply the aftermath of undetected acute injury. Researchers using Department of Veterans Affairs data followed 144,032 people starting acid suppression, censoring anyone at the point they had an acute kidney injury. Even excluding those people entirely, PPI users still showed higher rates of declining kidney function than H2 blocker users — incident CKD at 1.26, and end-stage disease or a greater than 50% drop in filtration rate at 1.30 [Xie et al., Kidney International, 2017].
Their conclusion was practical: waiting for an acute injury as a warning sign isn’t a sufficient safety strategy, because the chronic decline happens without one.
Why this still isn’t settled
Now the other side, and it’s substantial.
The COMPASS trial randomized 17,598 people with cardiovascular disease to pantoprazole 40mg daily or placebo, double-blind, and followed them for a median of three years — 53,152 patient-years in total. They collected data on pneumonia, C. difficile, fractures, gastric atrophy, chronic kidney disease, diabetes, dementia, cancer and death. The only outcome that reached statistical significance was enteric infections. Chronic kidney disease showed no significant difference [Moayyedi et al., Gastroenterology, 2019].
That’s the highest grade of evidence available on this question, and it found nothing.
Two caveats worth being fair about. Three years is a meaningful stretch but shorter than the decades some people spend on these drugs, and chronic kidney disease develops slowly. And the participants were cardiovascular patients rather than a general population. So COMPASS reduces the concern considerably without eliminating it.
Meanwhile, a systematic review applying formal bias assessment to 26 observational studies of PPIs and kidney outcomes judged 19 as having moderate risk of bias and six as serious, mostly due to inadequate control of confounders and selection bias. Effect estimates ranged wildly, from 0.24 to 7.34. The authors concluded that establishing causality from this literature is difficult [Rajan et al., Therapeutic Advances in Gastroenterology, 2022]. In fairness, that review was funded by a pharmaceutical company with a stake in the answer — which doesn’t make its methodology wrong, but is worth knowing.
My reading of it
The kidney signal is more credible than the dementia one. There’s an established mechanism through interstitial nephritis, a dose-response relationship, and consistency across large independent datasets. But the randomized evidence doesn’t support it, and the observational studies have known weaknesses.
The sensible position is precaution rather than alarm: don’t take more than you need, don’t take it longer than you need, and know your kidney numbers if you’ve been on it for years.
What this means if you have silent reflux
Here’s where it becomes more than an academic argument.
A great many people with LPR end up on twice-daily PPI dosing. That’s the standard escalation: throat symptoms don’t respond to once daily, so the dose is doubled, often for months. And twice-daily is precisely the dosing that showed the higher kidney risk.
The problem is that the escalation frequently isn’t buying much. The placebo-controlled trials of PPIs in laryngopharyngeal reflux are genuinely underwhelming, and the reason is mechanical: acid suppression doesn’t stop reflux happening. Pepsin still reaches your throat, binds to the tissue, and reactivates whenever something acidic passes through. Non-acid reflux is unaffected entirely. I’ve set out the full argument in why PPIs don’t work for LPR.
So the position a lot of people are in — double-dose PPI, years on end, throat still bad — is the worst version of this trade-off. Highest exposure, least benefit.
If your PPI is genuinely controlling erosive damage or you’re on it for stomach protection alongside NSAIDs or anticoagulants, that’s a different calculation entirely and the benefit clearly wins. The problem case is the drug that isn’t achieving anything measurable.
Practical steps
- Know your numbers. If you’ve been on a PPI for more than a year, ask for a kidney function test (eGFR and creatinine). It’s a routine blood test. This is the single most useful thing on this list.
- Question twice-daily dosing. If you’re on 40mg twice daily for throat symptoms that haven’t improved, that’s worth reviewing rather than continuing by default.
- Stay hydrated. Basic, but dehydration compounds any kidney stress, and plenty of people with reflux restrict fluids around meals.
- Watch the combinations. NSAIDs are hard on kidneys independently. Regular ibuprofen plus a long-term PPI is a combination worth discussing with your doctor.
- Don’t stop abruptly. Rebound acid hypersecretion is real and will convince you that you needed the drug. Getting off PPIs and acid rebound explains what happens and how to taper.
On that last point — the thing that determines whether coming off works isn’t the taper schedule, it’s whether you’ve dealt with the reflux itself first. Alginate rafts cover the transition well because they work as a physical barrier rather than by suppressing acid, but the diet has to be in place before you start reducing, not after. The Wipeout Diet Plan is what I’d have running for a few weeks before touching the dose.
Conclusion
The kidney concern deserves more respect than most PPI scares, and less panic than the headlines suggest. Acute interstitial nephritis is a real if uncommon risk. The chronic kidney disease link is plausible and consistently observed, but the one randomized trial large enough to test it didn’t find it. Precaution, monitoring, and not taking more than you need is the proportionate response.
What matters more for most people reading this is the second question: is the drug earning its place? If you have silent reflux and you’re on double-dose acid suppression with a throat that still feels raw, the honest answer is often no — and the way out isn’t a different tablet, it’s addressing what’s actually driving the reflux. The Wipeout Diet Plan is the complete protocol for that: the pH thresholds that decide whether a food reactivates pepsin in your throat, meal timing, the night-time routine, and a structured programme to work through rather than a list of foods to avoid. It was built first around LPR, the throat-based form where acid suppression disappoints most reliably, but since it works on the same root mechanisms it does the job equally well for GERD and everyday heartburn.
The Wipeout Food Reference Guide is the essential lighter companion — the foods and drinks that are safe for acid reflux and LPR alongside their pH values, so you can check anything at a glance. The Diet Plan is the programme; the guide is the reference beside it.
If you take one thing from this: ask for a kidney function test at your next appointment, and ask what your PPI is for. Both are small requests, and between them they resolve most of what’s worth worrying about here.
Frequently Asked Questions
Should I stop my PPI to protect my kidneys?
Not on your own, and not abruptly. If you’re taking it for erosive esophagitis, Barrett’s, or stomach protection with NSAIDs or anticoagulants, the benefit almost certainly outweighs an uncertain kidney risk. If you’re taking it for throat symptoms it isn’t improving, that’s worth a review with your doctor — which is a different thing from stopping.
How would I know if my kidneys were affected?
Usually you wouldn’t, which is the point. Early kidney impairment is typically silent. It’s picked up on a blood test measuring creatinine and eGFR. Symptoms like swelling, unusual fatigue or changes in urination tend to appear only at later stages, so testing is the only reliable answer.
Are H2 blockers safer for the kidneys?
The comparative studies used H2 blockers as the comparison group and generally found lower rates of kidney outcomes among them. That’s suggestive rather than conclusive. If acid suppression is genuinely needed and you’re concerned, it’s a reasonable conversation to have — famotidine versus omeprazole covers the trade-offs.
Does the risk go away if I stop?
Acute interstitial nephritis often improves substantially when the drug is withdrawn, particularly if caught early. Established chronic kidney disease doesn’t reverse, though stopping a contributing factor slows further decline. Another argument for testing sooner rather than later.
Is once-daily much safer than twice-daily?
In the observational data, meaningfully so — 1.15 versus 1.46. Whether that reflects the drug or the fact that people on double doses are sicker isn’t fully resolved. Either way, if you’re on twice-daily dosing without a clear reason, it’s worth asking whether you still need it.
I have existing kidney disease. Can I take a PPI?
That’s a question for your kidney doctor rather than an article. PPIs aren’t automatically off-limits in chronic kidney disease, but the risk-benefit calculation shifts and it should be a deliberate decision. Do raise it — don’t just keep collecting the repeat prescription.
Why do observational studies and randomized trials disagree so often?
Because observational studies compare people who chose or were given a drug against people who weren’t, and those groups differ in dozens of ways that are hard to fully adjust for. Randomization removes that problem by design. When the two disagree, the randomized evidence is usually closer to the truth — though a three-year trial can’t rule out effects that take fifteen years to appear.
Research & References
- [Lazarus et al., JAMA Internal Medicine, 2016] — In 10,482 participants from the Atherosclerosis Risk in Communities study, PPI use was associated with incident chronic kidney disease (adjusted hazard ratio 1.50), replicated in a cohort of 248,751 patients. Twice-daily dosing carried higher risk (1.46) than once-daily (1.15).
- [Xie et al., Kidney International, 2017] — Among 144,032 new users of acid suppression therapy, PPI users had higher rates of incident chronic kidney disease (1.26) and end-stage renal disease or major eGFR decline (1.30) than H2 blocker users, even when patients with intervening acute kidney injury were excluded.
- [Moayyedi et al., Gastroenterology, 2019] — Randomized double-blind trial of 17,598 participants given pantoprazole or placebo for a median of three years found no statistically significant difference in chronic kidney disease, fractures, pneumonia, dementia or mortality; only enteric infections were significantly increased.
- [Rajan et al., Therapeutic Advances in Gastroenterology, 2022] — Systematic review applying the ROBINS-I tool to 26 observational studies of PPIs and kidney outcomes judged 19 to carry moderate and six serious risk of bias, concluding that causality is difficult to establish from this evidence base.
David Gray
12 years living with LPR · Consultant & researcher
I've lived with LPR for twelve years — the misdiagnoses, the PPI courses that did nothing, the slow work of figuring out what actually helps. Wipeout Reflux is where I translate the research into plain terms for people stuck in the same place. Every claim here is sourced to peer-reviewed work, and I consult one-to-one with LPR sufferers.